Instructions for Derinat (Sodium deoxyribonucleate)
English Product Name
Derinat
Release Form
r-r d/o and local approx. 0.25%: fl-droplet. 10 ml 1 pc.; fl. 10 ml or 20 ml 1 pc.
Description Derinat
The solution for external and local use is 0.25% transparent, colorless, free from foreign inclusions.
1 ml
sodium deoxyribonucleate 2.5 mg
Auxiliary substances: sodium chloride, water d / i.
10 ml - bottle-droppers (1) - packs of cardboard.
10 ml - bottles with nozzle-spray (1) - packs of cardboard.
10 ml - glass bottles (1) - packs of cardboard.
20 ml - glass bottles (1) - cardboard packs.
ATX codes
L03A Immunostimulators
Clinical and pharmacological groups / Group affiliation
Immunomodulator
Active ingredient
sodium deoxyribonucleate
Pharmacotherapeutic group Derinat
Immunomodulatory agent
Retention conditions Derinat
The drug should be kept out of reach of children, in a dry, light-proof place at a temperature of 4° to 20° C.
Expiration date
The shelf life is five years.
The contents of the opened vial should be used for two weeks.
Pharmacological effect Derinat
Immunomodulator affecting cellular and humoral immunity. Derinate® stimulates reparative processes, has anti-inflammatory effect, normalizes the condition of tissues in case of dystrophic changes of vascular origin.
Said preparation activates antiviral, antifungal and antimicrobial immunity and exhibits a high reparative and regenerative action.
Applied externally, Derinate® promotes healing of trophic ulcers, infected wounds, and deep burns, greatly accelerating epithelization. Derinate acts as a cicatricial healing agent for ulcerative defects on the mucous membrane.
Testimony Derinat
- As monotherapy:
- prevention and treatment of SARS;
- ARI;
- Inflammatory and dystrophic eye diseases
- inflammatory diseases of the oral mucosa.
- As part of complex therapy:
- chronic inflammatory diseases, fungal, bacterial and other infections of mucous membranes in gynecology;
- Acute and chronic diseases of the upper respiratory tract (rhinitis, sinusitis /including frontitis, sinusitis/);
- Obliterative diseases of the lower limbs;
- Trophic ulcers
- Gangrene
- Infected wounds that do not heal (including diabetes)
- Burns
- frostbite;
- Postradiation necrosis of skin and mucous membranes
- hemorrhoids.
Method of use, course and dosage Derinat
Derynate® in the form of a solution for external and local use is pres ribed depending on the location of the pathological process.
The drug is given to children from the first day of life and adults.
For the prevention of SARS, two drops are placed in each bow passage two to four times a day for one to two weeks. When symptoms of respiratory disease appear, the preparation is inoculated with two to three drops in each nasal passage every 1-1.5 hours during the first day, then with two to three drops in each nasal passage three to four times/day. Duration of the course of therapy - from five days to 1 month.
For inflammatory diseases of the nasal cavity and sinuses, the preparation is buried in three to five drops in each nasal passage four to six times a day; the course duration is 7-15 days.
- Nosology Derinat (ICD codes)
- H10.2
- Other acute conjunctivitis
- H10.4
- Chronic conjunctivitis
- H16.2
- Keratoconjunctivitis (including that caused by external exposure)
- I73.0
- Raynaud's syndrome
- I73.1
- Thromboangiitis obliterans [Berger disease]
- I73.9
- Peripheral vascular disease, unspecified (including intermittent claudication, arterial spasm)
- I79.2
- Peripheral angiopathy in diseases classified elsewhere (including diabetic angiopathy)
- I83.2
- Varicose veins of lower extremities with ulcer and inflammation
- J00
- Acute nasopharyngitis (runny nose)
- J01
- Acute sinusitis
- J06.9
- Acute upper respiratory infection, unspecified
- J31
- Chronic rhinitis, nasopharyngitis, and pharyngitis
- J32
- Chronic sinusitis
- K12
- Stomatitis and allied lesions
- K62.8
- Other specified diseases of anus and rectum (including proctitis)
- K64
- Hemorrhoids and perianal venous thrombosis
- N76
- Other inflammatory diseases of vagina and vulva
- T30
- Thermal and chemical burns of unspecified site
- T33
- Superficial frostbite
- T79.3
- Posttraumatic wound infection, not elsewhere classified
